03/02/2026
🚨 Big News for Metabolic Health!🚨�
Lilly just launched the NEW Zepbound 4-dose KwikPen — and it’s a game-changer.
At UpState of Health, this upgrade means:�✨ More flexible dosing tailored to your exact needs�✨ Smoother titration for better tolerance and fewer side effects�✨ Fewer devices and a simpler experience each month�✨ Improved convenience for travel, busy schedules, and real life�✨ Same powerful results you expect from Zepbound
If you’ve been considering medication-assisted weight loss—or want a more customized dosing plan—this is your moment!
Eli Lilly launched a four-dose, single-patient use KwikPen device for its injectable obesity drug, tirzepatide (Zepbound).
The device gives patients an additional, potentially more convenient option for taking the drug: They can use one KwikPen to take four weekly doses instead of four single-dose vials. The FDA opened the door for the new tirzepatide delivery device when it approved a label expansion for the drug. https://mdsc.pe/3OBvNcy